10-K: Applied DNA Sciences Focuses on Therapeutic DNA, Explores Divestiture of Security Business in Strategic Shift

Applied DNA Sciences is prioritizing its Therapeutic DNA Production Services and exploring the potential divestiture of its DNA Tagging and Security Products and Services business segment.

Summary

• Applied DNA Sciences is a biotechnology company focused on developing and commercializing technologies to produce and detect DNA and RNA.
• The company operates in three primary business markets: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.
• The company's current growth strategy is to focus resources on the development and commercialization of its Therapeutic DNA Production Services, including expanding its contract development and manufacturing operation (CDMO).
• Management is conducting a strategic review that may result in the divestiture or closure of the DNA Tagging and Security Products and Services and/or MDx Testing Services segments.
• The company is exploring the potential divestiture of its DNA Tagging and Security Products and Services business segment, but there is no assurance that a divestiture will be completed.
• The company's Therapeutic DNA Production Services include the LineaDNA and Linea IVT platforms for manufacturing synthetic DNA and associated enzymes for nucleic acid-based therapeutics.
• The LineaDNA platform offers advantages over plasmid-based DNA manufacturing, including speed, scalability, purity, simplicity, and flexibility.
• The Linea IVT platform combines LineaDNA IVT templates with Linea RNAP to enable customers to produce mRNA therapies more efficiently.
• The company plans to offer several quality grades of Linea DNA, including GLP, GMP for starting materials, and GMP for drug substances.
• The company's MDx Testing Services include pharmacogenomics testing services (PGx) and testing for Mpox Clade I and Clade II.
• The company's DNA Tagging and Security Products and Services, marketed under the CertainT platform, are used for supply chain authentication, particularly in cotton.
• The company's revenues decreased from $13.4 million in fiscal 2023 to $3.4 million in fiscal 2024, primarily due to a decline in COVID-19 testing revenues.
• The company incurred a net loss of $7.1 million for the fiscal year ended September 30, 2024, and has an accumulated deficit of $309.7 million.
• The company has concluded that these factors raise substantial doubt about its ability to continue as a going concern.
• The company is seeking additional financing through public equity, private equity, or debt financings.
• The company received net proceeds of approximately $5.8 million from a registered direct offering in October 2024, bringing its cash balance to approximately $10.1 million as of November 30, 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a substantial net loss, accumulated deficit, and concerns about the company's ability to continue as a going concern. While there are positive aspects related to the company's technology and strategic shift, the overall sentiment is negative due to the financial instability and potential risks.

Positives

• The company is focusing on its Therapeutic DNA Production Services, which has a large market opportunity.
• The LineaDNA and Linea IVT platforms offer advantages over existing technologies.
• The company plans to offer GMP-grade LineaDNA for use in clinical and commercial mRNA therapeutics.
• The company has launched an expansion of its clinical testing services for the detection of Mpox to include testing for both Mpox Clade I and Clade II.
• The company has secured a multi-year commercialization agreement for its CertainT platform with Indus Group.

Negatives

• The company's revenues decreased significantly in fiscal 2024 due to a decline in COVID-19 testing demand.
• The company incurred a net loss of $7.1 million for the fiscal year ended September 30, 2024.
• The company has concluded that there is substantial doubt about its ability to continue as a going concern.
• The company is exploring the potential divestiture of its DNA Tagging and Security Products and Services business segment, which may result in restructuring costs.
• The company may require additional financing, which could dilute existing stockholders.
• The company is not in compliance with Nasdaq's minimum bid price requirements and may be delisted.

Risks

• The company has produced limited revenue, making it difficult to evaluate future prospects.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not successfully implement its business strategies, including achieving growth objectives.
• The company may require additional financing, which could dilute the ownership of existing stockholders.
• The company may modify its business strategy, including a possible divestiture or closing of its DNA Tagging and Security Products and/or MDx Testing Services segments.
• The company's emphasis on Therapeutic DNA Production Services may reduce its ability to maintain and expand its existing MDx Testing Services and DNA Tagging and Security Products and Services businesses.
• If the company is unable to expand its DNA manufacturing capacity, it could lose revenue.
• Rapidly changing technology and extensive competition in synthetic biology could make the company's services or products obsolete.
• The company will need to develop and maintain facilities that meet GMP.
• Pharmaceutical and biologic products are highly complex, and if the company or its collaborators are unable to provide quality and timely offerings, the business could suffer.
• Pharmaceutical and biologic-related revenue will be dependent on customer demand for manufacturing services.
• The company may be unable to consistently manufacture or source its products to the necessary specifications or in quantities necessary to meet demand.
• The markets for drug and biologic candidates and synthetic DNA are very competitive.
• The markets for the company's supply chain security and product authentication solutions are very competitive.
• The company competes with larger life science, pharmaceutical, and biotechnology companies.
• The company's intellectual property rights are valuable, and any inability to protect them could reduce the value of its products, services, and brand.
• Pharmaceutical and biologic-related revenue is generally dependent on regulatory approval, oversight, and compliance.
• If the FDA were to begin to enforce regulation of LDTs, the company could incur substantial costs and delays.
• If the company fails to comply with laboratory licensing requirements, it could lose the ability to offer its clinical testing services.
• The company may have conflicts of interest with its affiliates and related parties.
• Stockholders may suffer substantial dilution if certain provisions in the May 2024 Series Warrants or October 2024 Series D Warrants are utilized.
• The exercisability of the October 2024 Private Placement Warrants is contingent upon obtaining Warrant Stockholder Approval.
• If the company fails to comply with healthcare laws, it could face substantial penalties.
• If the company is unable to continue to retain the services of Dr. Hayward, it may not be able to continue its operations.
• There are a large number of shares of common stock underlying outstanding options and warrants, and the sale of these shares may depress the market price of the common stock.
• The company has received written notice from Nasdaq that it is not in compliance with Nasdaq's minimum bid requirements and may be delisted.

Future Outlook

The company expects future growth in revenues to be derived from its Therapeutic DNA Production Services and MDx testing services, as the latter transitions to a focus on genetic testing. The company will continue to update its business strategy and monitor the use of its resources regarding its various business markets.

Management Comments

• The Companys management is currently engaged in a strategic review of the Companys business segments that may result in the closure or divestiture of the Companys DNA Tagging and Security Products and Services and/or MDx Testing Services, as well as workforce reductions and potential management changes.
• We expect that based on available opportunities and our beliefs regarding future opportunities, we will continue to modify and refine our business strategy.

Industry Context

The company is operating in the rapidly growing fields of nucleic acid-based therapeutics and molecular diagnostics. The shift towards mRNA therapies and the need for supply chain security are driving demand for the company's technologies. The company faces competition from larger, well-established players in these industries.

Comparison to Industry Standards

• The company's LineaDNA platform is positioned as an alternative to traditional plasmid-based DNA manufacturing, which is used by companies like Aldevron and Charles River Laboratories.
• The company's Linea IVT platform competes with companies like MilliporeSigma and Thermo Fisher Scientific in the mRNA manufacturing space.
• The company's MDx Testing Services compete with established diagnostic companies like 23andMe, LabCorp, and Quest Diagnostics.
• The company's DNA Tagging and Security Products and Services compete with companies like Digimarc Corporation and Oritain Global Limited in the supply chain security market.
• The company's financial performance is significantly below industry standards, with a large net loss and accumulated deficit, while many competitors are profitable or have strong revenue growth.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to potential capital raises.
• Employees may be affected by potential workforce reductions.
• Customers may be impacted by changes in the company's business strategy.
• Suppliers may be affected by potential changes in the company's operations.

Next Steps

• The company plans to secure commercial-scale supply contracts for LineaDNA IVT templates and Linea RNAP.
• The company plans to utilize its GLP production capacity for non-IVT template applications to secure supply and/or development contracts with pre-clinical therapy developers.
• The company plans to develop LineaDNA production under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product.
• The company plans to convert new and existing LineaDNA IVT template customers to LineaIVT platform customers.
• The company intends to implement a reverse stock split of its outstanding securities to regain compliance with the Bid Price Rule.
• The company will hold a special meeting of shareholders to obtain Warrant Stockholder Approval.

Key Dates

Keywords

Therapeutic DNA Production, LineaDNA, Linea IVT, mRNA, Synthetic DNA, Biologics, CDMO, GMP, MDx Testing, PGx, Mpox, DNA Tagging, Supply Chain Security, CertainT, Biotechnology